News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

May 4, 2023 Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results
May 3, 2023 Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
April 27, 2023 Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results
April 24, 2023 Update on Open-Label Portion of the MERIDIAN Study Investigating Systemic Pegcetacoplan for Amyotrophic Lateral Sclerosis (ALS)
April 23, 2023 Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy
April 21, 2023 Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
April 17, 2023 Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign
April 6, 2023 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 6, 2023 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 1, 2023 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences